96. クローン病 Crohn disease Clinical trials / Disease details
臨床試験数 : 2,442 / 薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04660136 (ClinicalTrials.gov) | December 1, 2020 | 2/12/2020 | Usefulness of Contrast-enhanced Ultrasound (CEUS) in Crohn's Disease Pediatric Patients | Usefulness of Contrast-enhanced Ultrasound (CEUS) in Crohn's Disease Pediatric Patients | Crohn's Disease in Pediatric Patient | Biological: contrast enhanced ultrasound | Yonsei University | NULL | Recruiting | 2 Years | 18 Years | All | 20 | Phase 4 | Korea, Republic of |
| 2 | NCT02061163 (ClinicalTrials.gov) | February 2015 | 6/2/2014 | Contrast-Enhanced Ultrasound in Human Crohn's Disease | Evaluation of Contrast-Enhanced Ultrasound in Human Crohn's Disease | Crohn's Disease | Device: Contrast Enhanced Ultrasound;Drug: Optison | University of Michigan | NULL | Withdrawn | 10 Years | N/A | Both | 0 | Phase 1/Phase 2 | United States |
| 3 | EUCTR2015-002882-41-AT (EUCTR) | 05/11/2015 | A Pilot Study on the use of contrast enhanced ultrasound in Crohn’s disease | Sono-Response-StudyA Pilot Study on the use of contrast enhanced ultrasound in Crohn’s disease | Inflammatory bowel disease (Crohn's disease) MedDRA version: 18.1;Level: PT;Classification code 10011401;Term: Crohn's disease;System Organ Class: 10017947 - Gastrointestinal disorders;Therapeutic area: Diseases [C] - Digestive System Diseases [C06] | Trade Name: SonoVue Product Name: SonoVue INN or Proposed INN: sulphur hexafluoride Other descriptive name: SULFUR HEXAFLUORIDE | Medical University of Vienna (MUW) | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | Austria |